Urinary biomarkers suggest that estrogen-DNA adducts may play a role in the aetiology of non-Hodgkin lymphoma

Biomarkers

Volumn 14, Issue 7, 2009, Pages 502-512

  Gaikwad, Nilesh W ^a   Yang, Li ^a   Weisenburger, Dennis D ^b   Vose, Julie ^b   Beseler, Cheryl ^a   Rogan, Eleanor G ^a   Cavalieri, Ercole L ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Depurinating estrogen DNA adducts; Non Hodgkin lymphoma; Solid phase extraction; Urinary biomarkers

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN;

ADULT; AGED; ARTICLE; CANCER RISK; CLINICAL ARTICLE; CONJUGATE; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DNA ADDUCT; FOLLICULAR LYMPHOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LARGE CELL LYMPHOMA; LYMPHOBLASTOMA; LYMPHOCYTOMA; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; NONHODGKIN LYMPHOMA; PERIPHERAL T CELL LYMPHOMA; PROLYMPHOCYTIC LEUKEMIA; TANDEM MASS SPECTROMETRY; ULTRAPERFORMANCE LIQUID CHROMATOGRAPHY; URINALYSIS;

AGED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA; DNA ADDUCTS; ESTROGENS; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MOLECULAR STRUCTURE; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 70449354725     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/13547500903121715     Document Type: Article

References (49)

1. Alexander DD, Mink PJ, Adami H-O, Chang ET, Cole P, Mandel JS, Trichopoulos D. (2007). The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer 120S:1-39. (Pubitemid 46732571)
2. Bernstein L, Ross RK. (1992). Prior medication use and health history as risk factors for non-Hodgkin's lymphoma: preliminary results from a case-control study in Los Angeles County. Cancer Res 52:5510s-15s
3. Biro A, Pallinger E, Major J, Jakab MG, Klupp T, Falus A, Tompa A. (2002). Lymphocyte phenotype analysis and chromosome aberration frequency of workers occupationally exposed to styrene, benzene, polycyclic aromatic hydrocarbons or mixed solvents. Immunol Lett 81:133-140
4. Cao K, Stack DE, Ramanathan R, Gross ML, Rogan EG, Cavalieri EL. (1998). Synthesis and structure elucidation of estrogen quinones conjugated with cysteine, N-acetylcysteine, and glutathione. Chem Res Toxicol 11:909-916
5. Cavalieri EL, Stack DE, Devanesan PD, Todorovic R, Dwivedy I, Higginbotham S, Johansson SL, Patil KD, Gross ML, Gooden JK, Ramanathan R, Cerny RL, Rogan EG. (1997). Molecular origin of cancer: catechol estrogen-3,4- quinones as endogenous tumor initiators. Proc Natl Acad Sci U S A 94:10937-10942
6. Cavalieri EL, Kumar S, Todorovic R, Higginbotham S, Badawi AF, Rogan EG. (2001). Imbalance of estrogen homeostasis in kidney and liver of hamsters treated with estradiol: Implications for estrogen-induced initiation of renal tumors. Chem Res Toxicol 14:1041-1050
7. Cavalieri EL, Devanesan P, Bosland MC, Badawi AF, Rogan EG. (2002a). Catechol estrogen metabolites and conjugates in different regions of the prostate of Noble rats treated with 4-hydroxyestradiol: implications for estrogen-induced initiation of prostate cancer. Carcinogenesis 23:329-333
8. Cavalieri EL, Li KM, Balu N, Saeed M, Devanesan P, Higginbotham S, Zhao J, Gross ML, Rogan E. (2002b). Catechol ortho- quinones: the electrophilic compounds that form depurinating DNA adducts and could initiate cancer and other diseases. Carcinogenesis 23:1071-1077
9. Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R, Muti P, Rogan E, Russo J, Santen R, Sutter T. (2006). Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim Biophys Acta 1766:63-78.
10. Cerhan JR, Vachon CM, Habermann TM, Ansell SM, Witzig TE, Kurtin PJ, Janney CA, Zheng W, Potter JD, Sellers TA, Folsom AR. (2002). Hormone replacement therapy and risk of non-Hodgkin lymphoma and chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prevent 11:1466-1471
11. Chakravarti D, Mailander PC, Li KM, Higginbotham S, Zhang HL, Gross ML, Cavalieri E, Rogan E. (2001). Evidence that a burst of DNA depurination in SENCAR mouse skin induces errorprone repair and forms mutations in the H-ras gene. Oncogene 20:7945-7953
12. Chakravarti D, Zahid M, Backora M, Myers E, Gaikwad N, Weisenburger D, Cavalieri EL, Rogan EG, Joshi SS. (2006). Ortho-quinones of benzene and estrogen induce hyperproliferation of human peripheral blood mononuclear cells. Leuk Lymph 47:2635-2644
13. Devanesan P, Santen RJ, Bocchinfuso WP, Korach KS, Rogan EG, Cavalieri EL. (2001). Catechol estrogen metabolites and conjugates in mammary tumors with hyperplastic tissue from estrogen receptor-?cent; knock-out (ERKO)/Wnt-1 Mice: Implications for initiation of mammary tumors. Carcinogenesis 22:1573-1576
14. Ekstrom-Smedby K. (2006). Epidemiology and etiology of non-Hodgkin lymphoma - a review. Acta Oncologica 45:258-271
15. Farris GM, Everitt JI, Irons RD, Popp JA. (1993). Carcinogenicity of inhaled benzene in CBA mice. Fundamental and Applied Toxicology 20:503-507
16. Fernandez SV, Russo IH, Russo J. (2006). Estradiol and its metabolites 4-hydroxyestradiol and 2-hydroxyestradiol induce mutations in human breast epithelial cells. Int J Cancer 118:1862-1868
17. Forsberg JG. (1984). Short-term and long-term effects of estrogen on lymphoid tissues and lymphoid cells with some remarks on the significance for carcinogenesis. Arch Toxicol 55:79-90.
18. Gaikwad NW, Rogan EG, Cavalieri EL. (2007). Evidence from ESI-MS for NQO1-catalyzed reduction of estrogen ortho-quinones. Free Radic Biol Med 43:1289-1298
19. Gaikwad NW, Yang L, Muti P, Meza JL, Pruthi S, Ingle JN, Rogan EG, Cavalieri EL. (2008). The molecular etiology of breast cancer: evidence from biomarkers of risk. Int J Cancer 122:1949-1957
20. Gaikwad NW, Yang L, Pruthi S, Ingle JN, Rogan EG, Cavalieri EL. (2009a). Urinary biomarkers of risk in the molecular etiology of breast cancer. Breast Cancer Basic Clin Res 3:1-8.
21. Gaikwad NW, Yang L, Rogan EG, Cavalieri EL. (2009b). Evidence for NQO2-mediated reduction of the carcinogenic estrogen orthoquinones. Free Radic Biol Med 46:253-262
22. Grulich AE, Vajdic CM. (2005). The epidemiology of non-Hodgkin lymphoma. Pathology 37:409-419
23. Hayes RB, Yin SN, Dosemeci M, Li GL, Wacholder S, Travis LB, Li CY, Rothman N, Hoover RN, Linet M S. (1997). Benzene and the dose-related incidence of hematologic neoplasms in China. Chinese Academy of Preventive Medicine - National Cancer Institute Benzene Study Group. J Natl Cancer Inst 89:1065-1071
24. Huff JE, Haseman JK, DeMarini DM, Eustis S, Maronpot RR, Peters AC, Persing RL, Chrisp CE, Jacobs AC. (1989). Multiplesite carcinogenicity of benzene in Fischer 344 rats and B6C3F1 mice. Environ Health Perspect 82:125-163 (Pubitemid 19231543)
25. Li JJ. (1996). Perspectives in hormonal carcinogenesis: Animal models to human disease. Prog Clin Biol Res 394:447-454
26. Li KM, Todorovic R, Devanesan P, Higginbotham S, Kofeler H, Ramanathan R, Gross ML, Rogan EG, Cavalieri EL. (2004).Metabolism and DNA binding studies of 4-hydroxyestradiol and estradiol-3,4-quinone in vitro and in female ACI rat mammary gland in vivo. Carcinogenesis 25:289-297
27. Lu F, Zahid M, Wang C, Saeed M, Cavalieri EL, Rogan EG. (2008). Resveratrol prevents estrogen-DNA adduct formation and neoplastic transformation in MCF-10F cells. Cancer Prevent Res 1:135-145
28. Mailander PC, Meza JL, Higginbotham S, Chakravarti D. (2006). Induction of A.T to G.C mutations by erroneous repair of depurinated DNA following estrogen treatment of the mammary gland of ACI rats. J Steroid Biochem Mol Biol 101:204-215
29. Mehlman MA. (2006). Causal relationship between non-Hodgkin's lymphoma and exposure to benzene and benzene-containing solvents. Ann NY Acad Sci 1076:120-128
30. Miligi L, Costantini AS, Benvenuti A, Kriebel D, Bolejack V, Tumino R, Ramazzotti V, Rodella S, Stagnaro E, Crosignani P, Amadori D, Mirabelli D, Sommani L, Belletti I, Troschel L, Romeo L, Miceli G, Tozzi GA, Mendico I, Vineis P. (2006). Occupational exposure to solvents and the risk of lymphomas. Epidemiology 17:552-561
31. Muller AMS, Ihorst G, Mertelsmann R, Engelhardt M. (2005). Epidemiology of non-Hodgkin 's lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol 4:1-12.
32. O'Connor SR, Farmer PB, Lauder I. (1999). Benzene and non- Hodgkin's lymphoma. J Pathol 189:448-453
33. Saeed M, Zahid M, Rogan E, Cavalieri E. (2005). Synthesis of the catechols of natural and synthetic estrogens by using 2- iodoxybenzoic acid (IBX) as the oxidizing agent. Steroids 70:173-178
34. Skibola CF, Lightfoot T, Agana L, Smith A, Rollinson S, Kao A, Adamson P, Morgan GJ, Smith MT, Roman E. (2005a). Polymorphisms in cytochrome P450 17A1 and risk of non- Hodgkin lymphoma. Br J Haematol 129:618-621
35. Skibola CF, Bracci PM, Paynter RA, Forrest MS, Agana L, Woodage T, Guegler K, Smith MT, Holly EA. (2005b). Polymorphisms and haplotypes in the cytochrome P450 17A1, prolactin, and catechol- O-methyltransferase genes and non-Hodgkin lymphoma risk. Cancer Epidemiol Biomarkers Prev 14:2391-2401
36. Skibola CF, Curry JD, Nieters A. (2007). Genetic susceptibility to lymphoma. Haematologica 92:960-969
37. Skibola CF, Bracci PM, Halperin E, Nieters A, Hubbard A, Paynter RA, Skibola DR, Agana L, Becker N, Tressler P, Forrest MS, Sankararaman S, Conde L, Holly EA, Smith MT. (2008). Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma. PLoS ONE 3:e2816.
38. Smith MT, Jones RM, Smith AH. (2007). Benzene exposure and risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prevent 16:385-391
39. Stack DE, Byun J, Gross ML, Rogan EG, Cavalieri EL. (1996). Molecular characteristics of catechol estrogen quinones in reactions with deoxyribonucleosides. Chem Res Toxicol 9:851-859
40. Steinmaus C, Smith AH, Jones RM, Smith MT. (2008). Meta-analysis of benzene exposure and non-Hodgkin lymphoma: biases could mask an important association. Occup Environ Med 65:371-378
41. Swerdlow SH, Campo E, Harris NL and others., editors. (2008). WHO classification of tumours of the hematopoietic and lymphoid tissues. IARC, Lyon.
42. Tompa A, Major J, Jakab MG. 1994. Monitoring of benzene-exposed workers for genotoxic effects of benzene: improved-workingcondition- related decrease in the frequencies of chromosomal aberrations in peripheral blood lymphocytes. Mutat Res 304:159-165
43. Venugopal D, Zahid M, Mailander PC, Meza JL, Rogan EG, Cavalieri EL, Chakravarti D. (2008). Reduction of estrogen- induced transformation of mouse mammary epithelial cells by N-acetylcysteine. J Steroid Biochem Mol Biol 109:22-30.
44. Yang L, Gaikwad NW, Meza J, Cavalieri EL, Muti P, Trock B, Rogan E. (2009). Novel biomarkers for risk of prostate cancer. Results from a case-control study. Prostate 69:41-48
45. Zahid M, Kohli E, Saeed M, Rogan E, Cavalieri E. (2006). The greater reactivity of estradiol-3,4-quinone vs estradiol-2,3-quinone with DNA in the formation of depurinating adducts: implications for tumor-initiating activity. Chem Res Toxicol 19:164-172
46. Zahid M, Gaikwad N, Rogan EG, Cavalieri EL. (2007). Inhibition of depurinating estrogen-DNA adducts formation by natural compounds. Chem Res Toxicol 20:1947-1953
47. Zahid M, Gaikwad NW, Ali MF, Lu F, Saeed M, Yang L, Rogan EG, Cavalieri EL. (2008). Prevention of estrogen-DNA adduct formation in MCF-10F cells by resveratrol. Free Rad Biol Med 45:136-145
48. Zhang L, Rothman N, Li G, Guo W, Yang W, Hubbard AE, Hayes RB, Yin S, Lu W, Smith MT. (2007). Aberrations in chromosomes associated with lymphoma and therapy-related leukemia in benzene-exposed workers. Environ Mol Mut 48:467-474
49. Zhao Z, Kosinska W, Khmelnitsky M, Cavalieri EL, Rogan EG, Chakravarti D, Sacks P, Guttenplan JB. (2006). Mutagenic activity of 4-hydroxyestradiol, but not 2-hydroxyestradiol, in BB rat2 embryonic cells, and the mutational spectrum of 4- hydroxyestradiol. Chem Res Toxicol 19:475-479